The present invention generally relates to a coagulant composition. Specifically, the present invention relates to a coagulant composition comprising of Zea mays seed and method of preparation thereof. The coagulant composition comprising of Zea mays seed of the present invention possesses excellent antimicrobial properties and useful for water purification.
BACKGROUND OF THE INVENTION
[0002] Background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art. [0003] Uncontaminated water is very much essential for the development of a healthy immune system which is a necessary requirement for newborn and infants. Hard water can damage organs and even is a major cause of kidney stones. Usually, lead and chlorine are always present in normal tap water which is hazardous not for health but for skin. Water purifiers have filters which clear out the calcium and magnesium which is present in the water and make it soft again for the normal usage but are costly for poor people. Already existing chlorine water purification tablets uses the chemicals (chlorine/iodine/chlorine dioxide) that add to the water with these tabs, the disabled microorganisms and further contaminants remain in the water. The water still smells and looks the same as it was before using the water purification tablet. Turbid water stays turbid, don't remove odours or tastes They may even contribute to a bad taste of the water. [0004] Quality of water and its treatment has becoming an increasing concern in developing nations like in India, where the quality is poor, proper treatment is lacking. The high cost of treated water makes most people in rural communities to resort to readily available sources which are normally of low quality exposing them to water borne diseases. Safety and health are primary considerations for water purification. Access to save water is a serious issue affecting people of all ages for those living in remote communities and far flung areas where availability

of improved water sources is limited; it is a great challenge to impact quality of life in significant ways.
[0005] World Journal of Pharmaceutical Research, Volume 5, Issue 5, 1177-1185 discloses various natural coagulants for water purification.
5 [0006] No formulation made from natural constituents reported till date that can be used as water purifier. This research is carried out to confront the effectiveness of effervescent tablets made from powder extracted from matured dried Zea Mays, as active coagulant in water, which is readily available and commonly recognizable in most urban and rural communities of India.
0 [0007] There is, therefore, a need to develop an effective coagulant formulation comprising of natural active coagulant for water purification which is safe and economical.
OBJECTS OF THE INVENTION
5 [0008] An object of the present invention is to provide effervescent tablets of
phytoconstituent as water purifier.
[0009] Another object of the present invention is to provide an effervescent
tablet of Zea Mays with natural coagulation properties that helps to remove
hardness of water as well as colour of muddy water without altering pH. 0
SUMMARY OF THE INVENTION
[0010] The present invention generally relates to a coagulant composition.
Specifically, the present invention relates to a coagulant composition comprising
of Zea mays seed and method of preparation thereof. The coagulant composition 5 comprising of Zea mays seed of the present invention possesses excellent
antimicrobial properties and useful for water purification.
[0011] In one aspect, the present invention relates to a coagulant composition
comprising of:
(a) Zea mays seed;
0 (b) Citric acid;
(c) Tartaric acid;

(d) Sodium bicarbonate;
(e) one or more binding agents;
(f) Aspartame
(g) PEG600 and
5 (h) one or more flavoring agents.
[0012] In another aspect, the present invention relates to a coagulant composition comprising of:
(a) Zea mays seed powder;
(b) Citric acid;
0 (c) Tartaric acid;
(d) Sodium bicarbonate;
(e) one or more binding agents;
(f) Aspartame
(g) PEG600 and
5 (h) one or more flavoring agents.
[0013] In another aspect, the present invention relates to an effervescent tablet formulation comprising of:
(a) Zea mays seed powder;
(b) Citric acid;
0 (c) Tartaric acid;
(d) Sodium bicarbonate;
(e) one or more binding agents;
(f) Aspartame
(g) PEG600 and
5 (h) one or more flavoring agents.
[0014] In yet another aspect of the present invention, the one or more binding agent is Maltitol, Polyvinylpyrrolidone (PVP), or Mannitol.
[0015] In yet another aspect of the present invention, the one or more flavoring agent is strawberry flavor, lemon flavor or orange flavor.

[0016] In an embodiment of the present invention, the Zea mays seed or Zea
mays seed powder is present in an amount of 37.9% to 38.4% by weight of the
composition.
[0017] In an embodiment of the present invention, the citric acid is present in 5 an amount of 12.6% to 12.8% by weight of the composition.
[0018] In an embodiment of the present invention, the tartaric acid is present
in an amount of 1.5 % to 1.28 % by weight of the composition.
[0019] In an embodiment of the present invention, the Sodium bicarbonate is
present in an amount of 28 % to 28.2 % by weight of the composition. 0 [0020] In an embodiment of the present invention, the one or more binding
agents is present in an amount of 15 % to 15.8 % by weight of the composition.
[0021] In an embodiment of the present invention, the Maltitol is present in an
amount of 15% to 15.8 % by weight of the composition.
[0022] In an embodiment of the present invention, the aspartame is present in 5 an amount of 1.2 % to 1.28 % by weight of the composition.
[0023] In an embodiment of the present invention, the PEG600 is present in
an amount of 1.2 % to 1.28 % by weight of the composition.
[0024] In an embodiment of the present invention, the one or more flavoring
agent is present in an amount of 2.2 % to 2.5 % by weight of the composition. 0 [0025] In another aspect, the coagulant composition of the present invention is
in the form of powder, liquid, tablet or gel.
[0026] In yet another aspect, the present invention relates to method of
preparing an effervescent tablet formulation comprising of:
(a) Zea mays seed powder;
5 (b) Citric acid;
(c) Tartaric acid;
(d) Sodium bicarbonate;
(e) one or more binding agents;
(f) Aspartame;
0 (g) PEG600; and
(h) one or more flavoring agents.

[0027] In another aspect, the process for preparation of the an effervescent tablet formulation comprising the steps of:
(a) preparing slug using Zea mays seed fine powder;
(b) crushing the slug and passing through a sieve no. 20 to obtain 5 granulated Zee Mays seed powder;
(c) adding citric acid, tartaric acid, sodium bicarbonate, Maltitol,
Aspartame, PEG600 and strawberry flavor to the granulated Zee
Mays seed powder to obtain homogenous powder,
(d) compressing the homogenous powder to obtain effervescent
0 tablet.
[0028] In another aspect, the composition of the present invention possesses excellent antimicrobial activity.
[0029] In another aspect, the composition of the present invention is useful in water purification. 5 [0030] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
0 [0031] Figure 1 depicts the pH change of water before and after treatment of
Zea Mays seed powder effervescent tablets.
[0032] Figure 2 depicts the turbidity of water before and after treatment of
Zea Mays seed powder effervescent tablets.
[0033] Figure 3 illustrates the alkalinity of water before and after treatment of 5 Zea Mays seed effervescent tablets.
[0034] Figure 4 illustrates the hardness of water before and after treatment of
Zea Mays seed effervescent tablets.
[0035] Figure 5 is the flow diagram of effervescent table preparation.

DETAILED DESCRIPTION OF THE INVENTION
[0036] The following is a detailed description of embodiments of the disclosure. The embodiments are in such detail as to clearly communicate the disclosure. However, the amount of detail offered is not intended to limit the
5 anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the appended claims.
[0037] Unless the context requires otherwise, throughout the specification which follow, the word "comprise" and variations thereof, such as, "comprises"
0 and "comprising" are to be construed in an open, inclusive sense that is as "including, but not limited to."
[0038] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus,
5 the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
0 [0039] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.
5 [0040] In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term "about." Accordingly, in some embodiments, the numerical parameters set forth in the
0 written description are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some

embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable.
[0041] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. [0042] All processes described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention. [0043] The headings and abstract of the invention provided herein are for convenience only and do not interpret the scope or meaning of the embodiments. [0044] The following discussion provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.
[0045] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition

of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply. [0046] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be
5 referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written
0 description that follows, and the embodiments described herein, is provided by way of illustration of an example, or examples, of particular embodiments of the principles and aspects of the present disclosure. These examples are provided for the purposes of explanation, and not of limitation, of those principles and of the disclosure.
5 [0047] It should also be appreciated that the present invention can be implemented in numerous ways, including as a system, a method or a device. In this specification, these implementations, or any other form that the invention may take, may be referred to as processes. In general, the order of the steps of the disclosed processes may be altered within the scope of the invention.
0 [0048] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing. [0049] In a general embodiment, the present invention generally relates to a
5 coagulant composition. Specifically, the present invention relates to a coagulant composition comprising of Zea mays seed and method of preparation thereof. The coagulant composition comprising of Zea mays seed of the present invention possesses excellent antimicrobial properties and useful for water purification. [0050] The term "about" as used herein refers to a defined range of the value
0 by plus or minus 10 %. For example, about 2 % means 1.8 % to 2.2 %, about 5 %

means 4.5 % to 5.5 %, about 10 % means 9 % to 11 % and about 40 % means 36 % to 44 %.
[0051] As used herein, "Zea mays seed" refers to Indian corn or maize. [0052] In an embodiment, the present invention relates to an effervescent tablet formulation comprising of:
(a) Zea mays seed powder;
(b) Citric acid;
(c) Tartaric acid;
(d) Sodium bicarbonate;
(e) one or more binding agents;
(f) Aspartame;
(g) PEG600; and
(h) one or more flavoring agents. [0053] In another embodiment, the present invention relates to an effervescent tablet formulation comprising of:
(g) Zea mays seed powder;
(h) Citric acid;
(i) Tartaric acid;
(j) Sodium bicarbonate;
(k) Maltitol;
(1) Aspartame;
(g) PEG600; and
(h) one or more flavoring agents [0054] In another embodiment of the present invention, the effervescent table formulation composition comprises:
(a) Zea mays seed powder is present in an amount ranges from 37.9 % to 38.4 % by weight of the composition;
(b) Citric acid is present in an amount ranges from 12.59 % to 12.8 % by weight of the composition;
(c) Tartaric acid is present in an amount ranges from 1.5 % to 1.28 % by weight of the composition;

(d) Sodium bicarbonate is present in an amount ranges from 28 % to 28.2 % by weight of the composition;
(e) one or more binding agent is present in an amount ranges from 15 % to 15.8 % by weight of the composition;
5 (f) Aspartame is present in an amount ranges from 1.2 % to 1.28 % by
weight of the composition;
(g) PEG600 is present in an amount ranges from 1.2 % to 1.28 % by
weight of the composition; and
(h) one or more flavoring agents is present in an amount ranges from
0 2.2 % to 2.5% by weight of the composition.
[0055] In another embodiment of the present invention, the effervescent table formulation composition comprises:
(a) Zea mays seed powder is present in an amount ranges from 37.9 %
to 38.4 % by weight of the composition;
5 (b) Citric acid is present in an amount ranges from 12.59 % to 12.8 %
by weight of the composition;
(c) Tartaric acid is present in an amount ranges from 1.5 % to 1.28 %
by weight of the composition;
(d) Sodium bicarbonate is present in an amount ranges from 28 % to
0 28.2 % by weight of the composition;
(e) Maltitol is present in an amount ranges from 15 % to 15.8 % by weight of the composition;
(f) Aspartame is present in an amount ranges from 1.2 % to 1.28 % by weight of the composition;
5 (g) PEG600 is present in an amount ranges from 1.2 % to 1.28 % by
weight of the composition; and
(h) strawberry is present in an amount ranges from 2.2 % to 2.5% by weight of the composition. [0056] In another embodiment, the present invention relates to an effervescent 0 tablet formulation comprising of:
(a) about 37 % of Zea mays seed powder;

(b) about 12.5 % of Citric acid;
(c) about 2 % of Tartaric acid;
(d) about 28.4 % Sodium bicarbonate;
(e) about 15.7 % of one or more binding agents; 5 (f) about 1.2 % of Aspartame;
(g) about 1.2 % of PEG600; and
(h) about 2.3 % of one or more flavoring agents.
[0057] In another embodiment, the present invention relates to an effervescent
tablet formulation comprising of:
0 (g) about 37%) of Zea mays seed powder;
(h) about 12.5 % of Citric acid;
(i) about 2 % of Tartaric acid;
(j) about 28.4 % Sodium bicarbonate;
(k) about 15.7 % of Maltitol;
5 (1) about 1.2% of Aspartame;
(g) about 1.2 % of PEG600; and
(h) about 2.3 % of one or more flavoring agents. [0058] In another embodiment of the present invention, the Zea mays seed powder oils is present in an amount ranges from about 37.9% to about 38.4% by 0 weight of the composition of the present invention. Preferably, the Zea mays seed powder is present in an amount of 37.9%, 37.8% and 38.4% by weight of the composition.
[0059] In another embodiment of the present invention, the citric acid is present in an amount ranges from about 12% to about 13% by weight of the 5 composition of the present invention. Preferably in an amount of 12.59%, 12.69% and 12.8 % by weight of the composition.
[0060] In another embodiment of the present invention, the tartaric acid is present in an amount ranges from about 1% to about 2 by weight of the composition of the present invention. Preferably in an amount of 1.2%, 1.28% and 0 1.5%by weight of the composition.

[0061] In another embodiment of the present invention, the sodium
bicarbonate is present in an amount ranges from about 28% to about 29% by
weight of the composition of the present invention. Preferably in an amount of
28%, 28.4% and 28.2 % by weight of the composition.
[0062] In another embodiment of the present invention, the binding agent is
present in an amount ranges from about 15% to about 16% by weight of the
composition of the present invention. Preferably in an amount of 15%, 15.7% and
15.8 % by weight of the composition.
[0063] In another embodiment of the present invention, the aspartame is
present in an amount ranges from about 1% to about 2% by weight of the
composition of the present invention. Preferably in an amount of 1.2%, 1.21% and
1.28 % by weight of the composition.
[0064] In another embodiment of the present invention, the PEG600 is present
in an amount ranges from about 1% to about 2% by weight of the composition of
the present invention. More preferably in an an amount of 1.2%, 1.2% and 1.28%
by weight of the composition.
[0065] In another embodiment of the present invention, the one or more
flavoring agent present in an amount ranges from about 2% to about 3% by
weight of the composition of the present invention. More preferably in an an
amount of 2.2%, 2.3% and 2.5% by weight of the composition.
[0066] In an embodiment of the present invention, the one or more binding
agent is Maltitol. However, a person skilled in the art would appreciate that any
other binding agent, as known to or appreciated by a person skilled in the art can
be utilized to serve its intended purpose in the instant invention.
[0067] In an embodiment of the present invention, the one or more flavoring
agent is strawberry flavoring. However, a person skilled in the art would
appreciate that any other flavoring agent, as known to or appreciated by a person
skilled in the art can be utilized to serve its intended purpose in the instant
invention.
[0068] The present invention provides a simple and cost-effective method for
preparation of an effervescent tablet formulation of the instant composition.

[0069] In an embodiment, the process for preparation of an effervescent tablet formulation comprises the steps of:
(a) preparing slug using Zea mays seed fine powder;
(b) crushing the slug and passing through a sieve no. 20 to obtain
granulated Zee Mays seed powder;
(c) adding other ingredients to the granulated Zee Mays seed powder to
obtain homogenous powder,
(d) compressing the homogenous powder to obtain effervescent tablet.
[0070] In yet another embodiment of the present invention, the coagulant
composition is prepared in the form of gel, powder, or liquid. The person having
ordinary skill in the art would easily prepare the various forms of the coagulant
composition using the common general knowledge and routine experimentation
based on the composition of the present invention.
[0071] The coagulant composition of the present invention possesses excellent
antimicrobial properties.
[0072] In an embodiment, the powder extracted from matured dried Zea Mays
seed act as active coagulant in water.
[0073] In yet another embodiment, the coagulant composition of the present
invention is useful in the water purification process.
[0074] According to the present invention, the effervescent tablets comprising
of Zea Mays seed powder showed the effective results and reduced the total pH,
Turbidity, Alkalinity, Hardness upto significant limits.
[0075] While the foregoing describes various embodiments of the disclosure,
other and further embodiments of the disclosure may be devised without departing
from the basic scope thereof. The scope of the invention is determined by the
claims that follow. The invention is not limited to the described embodiments,
versions or examples, which are included to enable a person having ordinary skill
in the art to make and use the invention when combined with information and
knowledge available to the person having ordinary skill in the art.

EXAMPLES
[0076] The present invention is further explained in the form of following
examples. However, it is to be understood that the following examples are merely
illustrative and are not to be taken as limitations upon the scope of the invention.
[0077] Collection of Water Sample
[0078] The raw water sample was collected by immersing a sterilized plastic
container until it was full from Sukhna lake and ghaggar river, flowing through
Punchkula. The cap was inserted while it was still underway. The water was then
treated using prepared coagulant.
[0079] Collection and Identification of Seed
[0080] Fresh seeds of Zea mays used in this study were collected from the
local market and nearby locations.
[0081] Preparation of Seed Powder
[0082] The seeds were dried at ambient temperature for a period of 5 days
before crushing. The seeds were made into fine powder and the powder was
sieved through 1.18mm standard sieve size. The powder was collected in sterile
bottle with air tight cap.
[0083] EFFERVESCENT TABLET FORMULATION

Sr. No. Name of Ingredients Amount percentage
1. Zea mays seed powder 0.5 g 37.9 %
2. Citric Acid 0.166 g 12.59%
3. Tartaric Acid 0.02 g 1.5%
4. Sodium Bicarbonate 0.37 g 28%
5. Maltitol 0.20 g 15%
6. Aspartame 0.016 g 1.2%
7. PEG600 0.016 g 1.2%
8. Strawberry flavor 0.03 g 2.2 %
[0084] Effervescent tablets were prepared by direct compression method. Fine powder of seeds was prepared to slug. Then, the slugs crushed and passed through

a sieve No. 20. Other components were weighed and mixed with seeds granules to
obtain a homogeneous powder.
Evaluation of Tablets:
Pre-compressional evaluation
[0085] Determination of particle size
[0086] Sieve method was used for this test. Sieves of different meshes (20, 25,
30, 35, 40, 70 and 100) were selected and placed on top of each other. 100 g of
powder was placed on the upper sieve. After 10 min of mild shaking the amount
remaining on each sieve was collected. Average diameter of powder was
calculated by the following equation:
Tx.d.
I. 10°
d =
x; = Average size of both the upper and lower sieve
[0087] Bulk density
[0088] A quantity of accurately weighed powder from each formula was introduced in to the measuring cylinder and then the volume was noted. Bulk density was expressed in g/ml and determined by the following formula:
/>bulk=
' Vbulk
[0089] Tapped density
[0090] A quantity of accurately weighed powder from each formulation was
introduced into a measuring cylinder. The cylinder was hit from the height of 2.5
cm every 2 s, up to volume plateau. Tapped density was calculated from the
following formula:
/'tapped =
V tapped
[0091] Compressibility index andHausner's ratio
[0092] These terms explain flow properties of the powders. Compressibility
index was expressed in percentage. They were given by the following equation:

n XT, T A ,nn /»tapped-/ibulk
Compressibility Index = 100 x -
/) tapped
Hausner's Ratio =
/ibulk
[0093] Angle of repose
[0094] It was measured by fixed funnel method. A funnel was secured with its tip at a given height H, above graph paper that was placed on a flat horizontal surface. Granules were carefully poured through the funnel until the apex of the conical pile just touches the tip of the funnel. The angle of repose (a) was then calculated by measuring the height (h) and radius (r) of the heap of the formed powder or granules and putting the values in the equation.
- » hight
tan(rjr) = -
0.5 Base
Where, a = Angle of repose.
[0095] Post-compressional evaluation
[0096] Weight variation
[0097] Twenty tablets were weighed individually and the average weight was calculated. The individual weights were then compared with the average weight. The tablets will pass the test if not more than two tablets fall outside the percentage limit and none of tablet differs by more than double percentage limit.
[0098] Friability
[0099] A total of 20 tablets were weighed and placed in the friabilator
(Erweka, TAP, Germany) and then operated at 25 rpm for 4 min. The tablets were
then weighed again. The difference in the two weights was used to calculate
friability as follows:
Friability percent = (Weight of tablets before test - Weight after test)/(Weight of tablets before test) xl00.
[00100] pH of solution
[00101] One tablet was dissolved in purified water. After complete dissolution,
the solution pH was measured by a pH meter. This test was repeated 3 times for
each formulation.

[00102] Carbon dioxide content
[00103] One effervescent tablet was dissolved in 100 ml sulfuric acid 1 N and
weight variation was measured before and after dissolution. CO 2 content was
presented as mg. This experiment was conducted on three tablets for each
formulation.
[00104] Hardness
[00105] The tablet hardness was determined by hardness tester.
[00106] Effervescence time
[00107] A tablet was placed in a glass containing purified water and
effervescent time was measured by a stopwatch.
[00108] Thickness
[00109] Thickness was measured by using a calibrated dial caliper. 10 tablets
of each formulation were evaluated.
[00110] Assay
[00111] A tablet was placed in a 100 ml volumetric flask and dissolved in
phosphate buffer pH 5. After dilution, the amount of the drug was determined by
UV spectrophotometer at 229.8 nm against blank. 10 tablets of each formulation
were evaluated.
[00112] Content uniformity
[00113] After selecting 10 tablets randomly, the content of each tablet was
separately determined. Then, the above procedure was followed.
[00114] Anti-microbial activities:
[00115] The antimicrobial activity of the tablets was determined by the disc
diffusion method against E coli and S. aureus.
[00116] Example 2: PROCEDURE FOR WATER PURIFIER
[00117] Different concentrations of powdered seeds of Zea Mays into tableted
form was made by taking 0.5gm, 1.0 gm, 1.5 gm and then put into 1000 ml of
collected river water. The solution was shaken properly for 1 minute for activation
and extraction of coagulant and antimicrobial proteins in the seed powder and was
kept for magnetic stirring for 0.5 hour, 1 hour, 2 hours respectively. The treated

water was then allowed to stand undisturbed for 6 hours. Later, top layer of 100 ml was collected and subjected to post treatment analysis. [00118] Method Used for Physiological Study of Water [00119] For water sample, physiochemical parameters were determined prior and after treatment with seed solutions of Zea Mays The parameters determined were pH, Turbidity, Alkalinity, Hardness. [00120] RESULTS AND DISCUSSION
[00121] pH: With the present study treatment of Zea Mays seed powder tablet that was given to the raw water samples in different doses. During the analysis, it was observed that after treatment with Zea Mays; pH of sample was decreased from 8.5 to 7.3, 7.1, 7.0 for 0.5 gm/lit, 1.0 gm/lit, 1.5 gm/lit dose respectively [Table 1, Figure 1]. After treatment the range of pH was within the limit. [00122] Turbidity: The initial turbidity for the Raw water sample taken for Zea Mays was 42 NTU which was beyond the limits of BIS/GOLWHO standards. It was observed after treatment the turbidity got reduced from 42 NTU to 5.1, 3.2, 2.2 NTU for lgm/lit, 2gm/lit, 3gm/lit dose respectively [Table 1, Figure 2]. The turbidity reduced below 5 NTU. Due to this treatment there was an improvement in the flock size and flock settled rapidly. This analysis shows that with increase in dose of coagulants the turbidity got reduced to a good extent. [00123] Alkalinity: Alkalinity during the research work was observed to be 310 mg/litre for raw water but after treatment with Zea Mays seeds alkalinity got reduced to 150, 161, 110 mg/litre for for lgm/lit, 2gm/lit, 3gm/lit dose respectively [Table 1, Figure 3]. The alkalinity present was within the range of BIS/WHO/GOI standards. It was observed the seeds had the natural buffering capacity. The flocks were light however it confined the reduction of alkalinity. [00124] Hardness: Hardness was 232 mg/lit for raw water after treatment with Zea Mays the hardness got reduced to 135, 111, 105 mg/litre for lgm/lit, 2gm/lit, 3gm/lit dose respectively. It was observed that hardness of water is decreased with increase in dose of coagulants used. Hardness in raw water is due to the presence of calcium, magnesium and other hardness causing substances that means if hardness increases, the required dosage of seed powder increases.

[00125] Colour: The initial brown colour of raw water sample was completely removed after treatment with the formulation of present invention. The seeds show absorbent Properties.
[00126] Effervescent time: The effervescent time for all the formulations were less than 2 minutes that are within the range of Indian pharmacopeia standard. [00127] Antimicrobial activities: The Zea mays seed powder containing tablets showed excellent antimicrobial activities confirmed through disc diffusion zone
[00128] Table 1: Parameters studied before and after treatment of waste water for Zia Mays seed powder effervescent tablets

S.No. Parameters Before Treatm ent After Treatment (gm/Lit) BIS Standard


1 2 3

1. pH 8.9 7.3 7.1 7.0 6.5-8.5
2. Turbidity(NTU) 42 5.1 3.2 2.2 5max
3 Alkalinity(mg/lit) 310 150 161 110 200-600
4. Hardness(mg/lit) 232 135 111 105 500
5. Colour Brown Colourless Colourless
[00129] ADVANTAGES OF THE PRESENT INVENTION:
[00130] The advantageous properties of the instant formulation of the present invention is:
• Natural coagulant (Removes bacterial toxins)
• Remove turbidity and colour of muddy water due to adsorbing properties,
• Eco friendly
• Reduces hardness of water
• Rich source of protein
• Do not affect pH of water and
• Required in lesser quantities.

[00131] A skilled artisan will appreciate that the quantity and type of each ingredient can be used in different combinations or singly. All such variations and combinations would be falling within the scope of present disclosure [00132] The foregoing examples are merely illustrative and are not to be taken as limitations upon the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the scope of the invention.

We Claim:

1. A coagulant composition comprising of:
(a) Zea mays seed powder;
(b) Citric acid;
(c) Tartaric acid;
(d) Sodium bicarbonate;
(e) one or more binding agents;
(f) Aspartame;
(g) PEG600; and
(h) one or more flavoring agents.
2. An effervescent table formulation composition comprising of:
(a) Zea mays seed powder;
(b) Citric acid;
(c) Tartaric acid;
(d) Sodium bicarbonate;
(e) one or more binding agents;
(f) Aspartame;
(g) PEG600; and
(h) one or more flavoring agents.
3. The composition as claimed in claim 1 or 2, wherein the one or more binding agents is Maltitol, Polyvinylpyrrolidone (PVP), or Mannitol.
4. The composition as claimed in claim 1 or 2, wherein the one or more flavoring agents is strawberry flavor, lemon flavor, or orange flavor.
5. The effervescent table formulation composition as claimed in claim 2, wherein the composition comprises:

(a) Zea mays seed powder;
(b) Citric acid;
(c) Tartaric acid;
(d) Sodium bicarbonate;
(e) Maltitol;

(f) Aspartame;
(g) PEG600; and
(h) Strawberry flavor.
6. The effervescent table formulation composition as claimed in claim 2, wherein
the composition comprises:
(a) Zea mays seed powder is present in an amount ranges from 37.9 % to 38.4 % by weight of the composition;
(b) Citric acid is present in an amount ranges from 12.59 % to 12.8 % by weight of the composition;
(c) Tartaric acid is present in an amount ranges from 1.5 % to 1.28 % by weight of the composition;
(d) Sodium bicarbonate is present in an amount ranges from 28 % to 28.2 % by weight of the composition;
(e) one or more binding agent is present in an amount ranges from 15 % to 15.8 % by weight of the composition;
(f) Aspartame is present in an amount ranges from 1.2 % to 1.28 % by weight of the composition;
(g) PEG600 is present in an amount ranges from 1.2 % to 1.28 % by weight of the composition; and
(h) one or more flavoring agents is present in an amount ranges from 2.2 % to 2.5% by weight of the composition.
7. The effervescent table formulation composition as claimed in claim 2, wherein
the composition comprises:
(i) Zea mays seed powder is present in an amount ranges from 37.9 %
to 38.4 % by weight of the composition;
(j) Citric acid is present in an amount ranges from 12.59 % to 12.8 %
by weight of the composition;
(k) Tartaric acid is present in an amount ranges from 1.5 % to 1.28 %
by weight of the composition;
(1) Sodium bicarbonate is present in an amount ranges from 28 % to
28.2 % by weight of the composition;

(m) Maltitol is present in an amount ranges from 15 % to 15.8 % by
weight of the composition;
(n) Aspartame is present in an amount ranges from 1.2 % to 1.28 % by
weight of the composition;
(o) PEG600 is present in an amount ranges from 1.2 % to 1.28 % by
weight of the composition; and
(p) strawberry is present in an amount ranges from 2.2 % to 2.5% by
weight of the composition. 8. A process for preparation of an effervescent tablet formulation comprising the steps of:
(a) preparing slug using Zea mays seed fine powder;
(b) crushing the slug and passing through a sieve no. 20 to obtain granulated Zee Mays seed powder;
(c) adding citric acid, tartaric acid, sodium bicarbonate, Maltitol, Aspartame, PEG600 and strawberry flavor to the granulated Zee Mays seed powder to obtain homogenous powder, and
(d) compressing the homogenous powder to obtain effervescent table.